AmbAgon Therapeutics Inc.
Small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins
2
Funding Rounds
$92.2m
Money raised
Funding series
Funding Series Analysis
The company AmbAgon Therapeutics Inc. has raised a total of $85m in funding over 2 rounds.
Key Insights:
- AmbAgon Therapeutics Inc. Series A round, January 2022: $85m
- AmbAgon Therapeutics Inc. funding round, July 2020: $7.2m
AmbAgon Therapeutics Inc. Series A round, January 2022
$85m
AmbAgon Therapeutics Inc. funding round, July 2020
$7.2m
Industries
AmbAgon Therapeutics Inc. is active in the following industries: